Analysis of T-cell and NK-cell immunity in chronic myelogenous leukemia

Analysis of T-cell and NK-cell immunity in chronic myelogenous leukemia - Immunological analysis in CML

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020356

Enrollment

Registered

2015-12-26

Start date

2015-12-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myelogenous Leukemia (CML)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic myelogenous leukemia (CML) patients who take or will take TKIs.

Exclusion criteria

Exclusion criteria: Subjects who are determined to be unsuitable for enrolled in the present study by the physician.

Design outcomes

Primary

Measure	Time frame
Efficacy of TKIs in CML patients (Measurement of bcr-abl fusion gene)	—

Secondary

Measure	Time frame
T cell diversity and NK cell polymorphisms	—

Countries

Japan

Contacts

Public ContactTakero Shindo

Saga University School of Medicine Hematology, Respiratory Medicine and Oncology

takeros@cc.saga-u.ac.jp0952-31-6511

Outcome results